[Changes in Ca++ regulated process courses in synaptic transmission in psychoses? Commentary and work hypotheses].
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D002147:Calmodulin / Q000378:metabolism; D006801:Humans; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000378:metabolism; D011618:Psychotic Disorders / Q000188:drug therapy / Q000378:metabolism*; D013569:Synapses / Q000378:metabolism*; D013570:Synaptic Membranes / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects
D014150:Antipsychotic Agents; D002147:Calmodulin; D007473:Ion Channels; D018377:Neurotransmitter Agents; D002118:Calcium
Anderungen Ca++-regulierter Prozessabläufe der synaptischen Transmission bei Psychosen?